Dicerna Collaboration and Partnering
At Dicerna, we believe that strategic partnerships, research collaborations and licensing arrangements should add value to both parties, assisting each in attaining goals beyond those that could be achieved individually. GalXCTM is a proprietary technology platform that advances the development of next-generation RNAi-based therapies designed to silence disease-driving genes in the liver. Our GalXC RNAi technology platform supports Dicerna’s long-term strategy to retain a full or substantial ownership stake and invest internally for diseases with focused patient populations, such as certain rare diseases, as we see such diseases as representing opportunities that carry high probabilities of success, have easily identifiable patient populations and a limited number of Centers of Excellence to facilitate reaching these patients, and have the potential for more rapid clinical development programs. For more complex diseases with multiple gene dysfunctions and larger patient populations, we plan to pursue partnerships that can provide the enhanced scale, resources and commercial infrastructure required to maximize these prospects.
Our ideal industry partners help us to more efficiently use our proprietary RNAi technology platform to build a broad pipeline of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral infectious diseases. Tactical collaborations with other industry leaders allow us to maximize the potential of our programs to promote faster and more efficient development. Through these partnerships, we will advance product development and commercialization, leading to the availability of new therapies.
The Dicerna team is eager to discuss collaborative opportunities utilizing our RNAi platform across multiple indication areas.
Please contact Jim Weissman, Chief Business Officer, at (617) 612-6214 or email@example.com regarding the company’s partnering strategy.
In December 2009, Dicerna entered into a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. (KHK), a global pharmaceutical company, for the research, development and commercialization of Dicer substrate short-interfering RNA (DsiRNA) molecules for therapeutic targets, primarily in oncology. As part of this agreement, KHK is developing a product candidate that targets the oncogene KRAS, which is frequently mutated in numerous major cancers, including non-small cell lung cancer, colorectal cancer and pancreatic cancer. KHK is responsible for global development of the KRAS program, including all development expenses. For the KRAS product candidate, we retain an option to co-promote in the U.S. for an equal share of the profits from U.S. net sales. KHK is also developing a product candidate targeting an undisclosed oncogene. Visit Website